loading page

The Problematic Lag between FDA Approval of Medical Devices and CMS Coverage
  • +2
  • Bradley Knight,
  • Thomas Deering,
  • Michael Gold,
  • Suneet Mittal,
  • Jagmeet Singh
Bradley Knight
Northwestern Medical Center
Author Profile
Thomas Deering
Piedmont Heart Institute Arrhythmia Center
Author Profile
Michael Gold
MUSC
Author Profile
Suneet Mittal
Valley Health System
Author Profile
Jagmeet Singh
Harvard Medical School
Author Profile

Abstract

Significant changes or cancellation of MCIT could result in limiting access to breakthrough medical technologies that could improve the health and well-being of Medicare beneficiaries. For these reasons, we encourage federal agencies to work together and CMS to implement the MCIT rule without delay to ensure timely access to breakthrough technologies

Peer review status:ACCEPTED

21 Apr 2021Submitted to Journal of Cardiovascular Electrophysiology
21 Apr 2021Assigned to Editor
21 Apr 2021Submission Checks Completed
21 Apr 2021Review(s) Completed, Editorial Evaluation Pending
21 Apr 2021Editorial Decision: Accept